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ABSTRACT: In order to assess whether variations affecting
DNA mismatch repair (MMR) genes are pathogenic and
hence predisposing to Lynch syndrome (LS), a three-step
assessment model has been proposed. Where LS is
suspected based on family history, STEP1 is dedicated to
the identification of the causative MMR gene and the
variation within it. Thereafter, in STEP2 of the assessment
model, the effect of the variation on the function of the
protein is assessed in an in vitro MMR and in silico assays.
Where LS cannot be confirmed or ruled out in STEP2, the
more specific biochemical laboratory assays such as
analyzing the effect of the variation on expression,
localization, and interaction of the protein are required in
STEP3. Here, we verified the proposed three-step assess-
ment model and its ability to distinguish pathogenic MMR
variations from variants of uncertain significance (VUS) by
utilizing the clinical as well as the laboratory and in silico
data of 37 MLH1,2 6MSH2, and 11 MSH6 variations.
The proposed model was shown to be appropriate and
proceed logically in assessing the pathogenicity of MMR
variations. In fact, for MMR deficient MSH2 and MLH1
variations the first two steps seem to be sufficient as STEP3
provides no imperative information concerning the variant
pathogenicity. However, the importance of STEP3 is seen
in the assessment of MMR proficient variations showing
discrepant in silico results as their pathogenicity cannot be
confirmed or ruled out after STEP2. MSH6 variations may
be applicable to the model if appropriate selection in terms
of ruling out MLH1 and MSH2 variations and MLH1
promoter hypermethylation is ensured prior to the
completion of STEP2. In conclusion, taking into con-
sideration the susceptibility gene the three-step model can
be utilized in an appropriate and efficient manner to
determine the pathogenicity of MMR gene variations.
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Introduction
Lynch syndrome (LS, often referred to as hereditary non-
polyposis colorectal cancer syndrome; HNPCC; MIM] 120435) is
highly associated with autosomal dominant inheritance of
mutations in genes fundamental to the DNA mismatch repair
(MMR) mechanism. The most frequently affected genes include
MLH1 (MIM] 120436, RefSeq NM_000249.3), MSH2 (MIM]
609309, RefSeq NM_000251.1), MSH6 (MIM] 600678, RefSeq
NM_000179.2), and PMS2 (MIM] 600259, RefSeq NM_000535)
whose germline variations are reported in the LOVD database
(http://www.insight-group.org/; http://www.lovd.nl/). Although,
the majority of mutations affecting MMR genes are truncating, a
significant proportion of mutations result in a single amino acid
substitution or an in-frame deletion and are difficult to
distinguish from harmless polymorphisms. Such alterations are
often referred to as variants of uncertain significance (VUS)
[Goldgar et al., 2008] due to the uncharacterized effect of the
variation on the function of the polypeptide.
LS-associated tumors generally occur in the colon; nevertheless, a
variety of extracolonic carcinomas, especially those of the
endometrium, are also frequently observed. The mean age of
cancer onset in LS is significantly lower than that of sporadic
colorectal cancer (CRC) [Lynch and de la Chapelle, 1999] based on
the fact that in LS, an individual has already inherited susceptibility
through a mutated allele and only needs a second hit in a somatic
cell to lose MMR activity and start tumorigenesis. Hence, LS
tumors are characterized by the lack or lowered level of a causative
MMR protein as well as impaired DNA repair causing microsatellite
instability (MSI) [Aaltonen et al., 1993]. The wide variety of clinical
phenotypes complicates LS diagnostics and several clinical guide-
lines have been established to distinguish LS families from the
general CRC burden. Currently, the clinical diagnosis of LS greatly
relies on the Amsterdam criteria (AC) [Vasen et al., 1991, 1999] or
the revised Bethesda guidelines [Umar et al., 2004], which take into
account the age of cancer onset, the number and segregation of
affected individuals in a family, and the level of MSI. However,
many putative LS families do not fit these criteria and could be
confirmed as LS families only by characterizing a pathogenic
germline MMR gene mutation in them.
The first clinical step in diagnosing LS associated tumors
includes immunohistochemistry (IHC) and MSI analysis followed
by mutation analysis dictated by the IHC and MSI results. Hampel
et al. [2005] have proposed a strategy for screening LS by
analyzing all four MMR genes (MLH1, MSH2, MSH6, and PMS2)
together with the potential hypermethylation of the MLH1
promoter region. When a variation with a known defect is found,
LS can be confirmed or in the absence of a MMR gene variation,
ruled out.
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E-mail: minna.nystrom@helsinki.fiBased on a similar approach (STEP1), Couch et al. [2008] have
proposed a decision tree for the in vitro analysis of MMR VUS
found in putative LS families. This model utilizes data from
incompletely validated assays supplemented with data derived
from other sources for classification of VUS for clinical purposes.
More specifically, data derived from an in vitro MMR and in silico
analyses should be considered upon the identification of a VUS
(STEP2). Variations showing MMR deficiency in these assays
indicate LS, whereas variations with no apparent MMR deficien-
cies require a selection of biochemical assays for further
characterization of the effect of the variation on the protein
expression or function (STEP3).
Here, we aim to verify the ability of the proposed three-step
model in assessing pathogenicity with the data of 74 MMR gene
VUS including results of tumor pathologic, genetic, biochemical,
and in silico analyses.
Materials and Methods
MLH1, MSH2, and MSH6 Variations and Clinical Data
This study comprises 37 MLH1 (NM_000249.3) [Christensen
et al., 2009; Raevaara et al., 2005], 26 MSH2 (NM_000251.1)
[Christensen et al., 2009; Kariola et al., 2003; Ollila et al., 2006, 2008],
and 11 MSH6 (NM_000179.2) [Kariola et al., 2002, 2003, 2004]
variations. Nucleotide numbering reflects cDNA with 11c o r r e -
sponding to the A of the ATG translation initiation codon in the
reference sequence, according to journal guidelines (www.hgvs.org/
mutnomen). The family history and the data of mutation, MSI and
IHC analysis were mainly collected through an international LS
collaboration. Because the 74 VUS included in the study were found
by many research groups, different methods were used for mutation
detection. The alterations are distributed over most of the known
functional domains of the respective proteins as seen in the schematic
representations presented in the results section. MLH1 variations
tend to cluster either at the amino te r m i n a lo rc a r b o x y lt e r m i n a lo f
the protein, whereas MSH2 and MSH6 variations are dispersed
throughout the length of the proteins, with preferential location in
functional domain clusters seen particularly in the connector and
ATPase domains of MSH2. The variations were constructed by site-
directed mutagenesis and coexpressed with their native heterodimer-
ization partners in Spodoptera frugiperda (Sf9) insect cells for protein
production [Nystro ¨m-Lahti et al., 2002].
T h eV U Sc h o s e nf o rt h i ss t u d ya r ef r o mp u t a t i v eL Sf a m i l i e se i t h e r
fulfilling the AC, or from families not fulfilling AC but presenting LS
tumors at an abnormally low age, or with an excessive amount of LS
cancers occurring within the family. In fact, of the 37 MLH1
variations, at least 27 are associated with a mean age of onset below
50 years even though the ACI are only fulfilled by families associated
with 17 of the variations. Nineteen out of 26 MSH2 variations are
associated with a mean age of onset under 50 years and
approximately half of all the MSH2 variations were found in families
fulfilling ACII. MSH6 variations chosen for functional assessment
were mainly picked from the LOVD database. The families with
MSH6 variations do not fulfill AC, but instead, all but two variations
have been linked to the MSI-high (MSI-H) tumor phenotype. The
mean age of tumor onset of MSH6 VUS carriers is 59.
Functional Analyses
The 74 MMR gene VUS included in the verification study were
functionally characterized in our previous studies [Christensen
et al., 2009; Kariola et al., 2002, 2003, 2004; Ollila et al., 2008;
Raevaara et al., 2005]. Studies were typically mandated by clinical
questions and ambiguities tracking the variation, tumor pathology
data, or in some cases database information. The present study is
based on assessments performed in those studies, where
functionality of each variation was evaluated in comparison to
the performance of the corresponding wild-type (wt) protein and
functionally deficient negative controls. Assay results were
composed of a minimum of three independent experiments and
a repeatedly seen decrease in functionality compared to the
corresponding result of WT protein indicated pathogenicity.
The applied in vitro MMR assay [Nystro ¨m-Lahti et al., 2002]
uses a homologous human MMR system to study the ability of the
variant protein to repair a GTmispair. The standard deviation of
the repair efficiency of the deficient variant protein remained
below that of the WT protein. To assess the effect of the variation
on protein expression, MSH2 and MSH6 variant proteins were
expressed in Sf9 insect cells [Kariola et al., 2002], where as MLH1
proteins were expressed in 293T human cells. Thereafter, the
expression levels of the VUS proteins were compared with that of
WT protein by Western blot analysis [Raevaara et al., 2003].
Results from interaction studies are based on coimmunoprecipita-
tion and subsequent Western blot analysis of the variant protein
with its native heterodimerization partner [Kariola et al., 2002;
Raevaara et al., 2003]. To study whether the MLH1 variations
affect the subcellular localization, VUS cDNAs were fused with the
fluorescent protein EGFP cDNA and transiently expressed in 293T
cells [Raevaara et al., 2005]. The variants acting like WT MLH1
were classified as normal in the localization study.
In Silico Analysis by SIFT and MAPP-MMR
In silico methods take a computational approach to identify
highly conserved areas of a gene through a multiple sequence
alignment analysis across numerous species, and thereafter, deduce
possible functional defects of a variation. Several prediction
algorithms are available for in silico analyses. Here, the sorting
intolerant from tolerant (SIFT) [Ng and Henikoff, 2001] (http://
sift.jcvi.org/) and the multivariate analysis of protein polymorph-
ism (MAPP-MMR) [Chao et al., 2008; Stone and Sidow, 2005]
(http://mendel.standofrd.edu/SidowLab/) programs were chosen
for in silico assessment of the 74 VUS due to their high sensitivity
and specificity [Tavtigian et al., 2008b]. The results from
previously done SIFT analyses for MLH1 and MSH2 VUS
[Christensen et al., 2009; Ollila et al., 2006, 2008; Raevaara
et al., 2005] were complemented with results of MSH6 VUS
obtained from the LOVD database (http://www.lovd.nl/). The
MAPP-MMR analysis was performed here for the MLH1 and
MSH2 variations but was not available for MSH6 variations.
Neither of the programs can be applied to in frame deletions.
Verification of the Three-Step Model
To assess the pathogenicity of VUS, a three-step model
proposed by Couch et al. [2008] was applied (Fig. 1). The model
acknowledges the importance of appropriate VUS identification
by emphasizing the use of family history, MSI, and IHC data to
ultimately identify the VUS by genetic testing analysis in STEP1.
Upon the identification of a VUS, STEP2 consists of in vitro MMR
and in silico analyses. MMR deficiency demonstrated by STEP2
confirms LS, whereas in the case of MMR proficient variations, a
panel of biochemical assays is recommended in STEP3.
The 74 MMR VUS included in this study are found in families
suspected to have LS, and hence compose an appropriate and realistic
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model. Each variation is taken through the model and the assays
constituting each of the steps. Results indicating pathogenicity are
distinguished from ones indicating no effect of the variation.
Discrepancies between individual tumor data (IHC and MSI) as
well as between results from different in silico programs are marked.
STEP1 of the model proposed by Couch et al. [2008] is
represented by the family history and tumor pathology data of the
proband leading to mutation analysis. Tumors with two or more
unstable Bethesda panel markers [Umar et al., 2004] were considered
to have a high degree of MSI, and the lack or reduction of the MMR
protein in IHC was considered to indicate protein deficiency.
Upon the identification of a VUS, STEP2 of the assessment
model [Couch et al., 2008] suggests to combine the results of a
functional in vitro MMR assay with those of an in silico analysis.
Here, STEP2 is composed of the results of the in vitro MMR assay
and two separate in silico assays derived from the SIFTand MAPP-
MMR programs. Pathogenicity of a VUS was indicated by the in
vitro MMR assay alone or together with the deleterious results
obtained in silico as well as by deleterious results obtained through
both of the in silico methods even in the absence of such indication
by the in vitro MMR assay. Where pathogenicity in STEP2 was
suggested by only one in silico analysis, STEP3 with further assays
were required. Nonpathogenic VUS were distinguished by fully
completed STEP2 assays with no indication of pathogenicity.
STEP3 of the assessment model [Couch et al., 2008] is composed
of a set of laboratory experiments taken to further clarify the
pathogenicity of the variations, where previous steps did not already
do so. This panel of experiments was suggested to include studies of
protein stability, protein interaction, and subcellular localization.
STEP3 assays study specific fragments of the repair process
complementing the in vitro MMR assay, which was performed in
nuclear extracts and optimized to reveal even the slightest repair,
and thus, not able to discover problems in subcellular localization
or mild problems in protein stability or interactions. Here, the
STEP3 assays differ slightly between the three genes but have been
included for all variations for the verification of the three-step
model. Together with one deficient result from an in silico assay, a
decrease in variant protein expression, interaction, or localization
was considered to be an indication of pathogenicity. Consequently,
a single indication of pathogenicity in STEP3, although measuring
different aspects of the protein function than the MMR assay, was
deemed sufficient to confirm variant pathogenicity.
In order to verify the three-step model and determine the necessity
and validity of all three steps in it, results and interpretations after
S T E P 2a n dS T E P 3w e r ec o m p a r e d .F i n a l l y ,S T E P 1d a t aw a s
considered together with these comparisons to further verify the
indications of pathogenicity and to form a consensus for each step of
the model.
Results
Verification of the Three-Step Model with MLH1 Variations
Our results show that, if strong evidence from the family history,
MSI and IHC results give an indication of LS and an MLH1
variation has been detected in STEP1, STEP2 is often sufficient to
confirm the pathogenicity of the variation. As seen in Table 1, when
STEP2 results unanimously indicate pathogenicity (11/37), the
expression and localization analyses of STEP3 serve to confirm the
results and are hence descriptive but not essential for assessment.
This is also apparent when MMR proficiency is unanimously
indicated by all STEP2 assays as seen in 7/37 variations. Assuming
that pathogenicity can be shown with the in vitro MMR assay alone
(5/37) or with two deleterious in silico indications (4/37), STEP2 is
sufficient to confirm the pathogenicity of 20/37 MLH1 VUS. The
former requisite is supported by VUS for which the in silico results
are not obtainable, because all the five MLH1 deletions (p.T45_I47-
delinsCF, p.E71del, p.I330del, p.P578_E632del, and p.E633_E663-
del) indicated to be pathogenic by the in vitro MMR assay, are
confirmed to be so by STEP3, regardless of the lack of in silico
results. Likewise, the 4 MLH1 VUS (p.L550P, p.P648L, p.P648S, and
p.654L) indicated to be pathogenic by both in silico analyses, but
not with the MMR assay, are confirmed to be so by STEP3.
Nevertheless, in the absence of in silico results, or if
pathogenicity is indicated by only one alignment analysis, the
MMR proficiency is not sufficient to rule out pathogenicity. This
is indicated by MMR proficient MLH1 p.H329P, p.A589D,
p.V612del, p.K616del, and p.K618T that display reduced expres-
sion and/or nuclear localization in STEP3. Generally, in such cases
the expression assay suffices for STEP3. Especially, results from
MLH1/PMS2 protein interaction analysis appear to have very little
contribution toward the assessment of MLH1 VUS. In contrast,
four variants (p.K618A, p.Y646C, p.A681T, and p.R687W), in
which the STEP2 differences are due to an indication of
pathogenicity by only one in silico assay, the pathogenicity is
not confirmed by STEP3. Similarly, for MLH1-p.E460A, deficiency
indicated by only SIFT is not confirmed by STEP3.
The verification of the three-step model with the MLH1
variations demonstrates that STEP3 often supports the deduc-
tions, which, however, can be made from STEP2 analyses in the
case of 27/37 variations. Only in the case of MMR proficient
variations with either discrepant or no data from both in silico
methods, STEP3 is required for interpretation (10/37).
Verification of the Three-Step Model with MSH2 Variations
As with the variations affecting MLH1, when the MMR assay
results agree with those obtained in silico, STEP3 is not necessary.
Figure 1. A three-step decision tree proposed to facilitate the
functional assessment of VUS. (Modified from Couch et al. [2008].)
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MSH2 variations (Table 2). Pathogenicity indicated by the in vitro
MMR assay result or with two deleterious in silico results confirms
the pathogenicity of 15 VUS raising the total number of
successfully assessed VUS in STEP2 to 22 out of 26. Notably, no
indication of pathogenicity is seen in STEP3 only.
U n l i k ei nt h ec a s eo fs o m eMLH1 variations, the pathogenicity of
MSH2 variations (p.T44M, p.N127S, p.V722I and p.A834T)
indicated by only one in silico assay cannot be confirmed by STEP3
assays. MSH2-p.T44M has poor availability of clinical data, whereas
the other three VUS (p.N127S, p.V722I, p.A834T) have been found
in individuals with other MMR gene variations. Remarkably, a total
Table 1. Verification Data of MLH1 Variations
Step 1  MLH1 (NM_000249.3)  Step 2  Step 3 
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Nucleotide
changec
Amino acid
change
         c.83C>T p.P28L      
      c.85G>T   p.A29S
f               
    c.133_141delinsTGTTTT  p.T45_I47delinsCF
      c.189C>A   p.D63E
         c.199G>A   p.G67R
      c.211_213del  p.E71del      
         c.229T>C   p.C77R
         c.238T>G   p.F80V         
         c.250A>G   p.K84E         
            c.277A>G   p.S93G               
      c.320T>G   p.I107R
      c.464T>G   p.L155R
      c.554T>G   p.V185G
c.637G>A   p.V213M               
               c.655A>G   p.I219V               
      c.739T>C   p.S247P
      c.986A>C   p.H329P
      c.988_990del  p.I330del
      c.1327A>C   p.K443Q               
      c.1379A>C   p.E460A
f                
     c.1649T>C   p.L550P
        c.1734_1896del   p.P578_E632del         
     c.1766C>A   p.A589D
           c.1834_1836del   p.V612del      
      c.1846_1848del  p.K616del      
         c.1852_1853AA>GC   p.K618A
f            
         c.1853A>C   p.K618T      
               c.1897_1989del  p.E633_E663del
         c.1937A>G   p.Y646C            
         c.1943C>T   p.P648L
      c.1942C>T   p.P648S
      c.1961C>T   p.P654L
      c.1976G>C   p.R659P
      c.1976G>A   p.R659Q
f               
         c.2041G>A  p.A681T            
c.2059C>T   p.R687W            
         c.2146G>A   p.V716M               
a
b
tumor data (MSI and IHC); A diagonal line, data not available. 
c
sequence, according to journal guidelines (www.hgvs.org/mutnomen).
d
e
MMR only; A diagonal line, data not available; Vertically divided field indicates the availability of one result only.
f
Black, ACI fulfilled; White, ACI not fulfilled; Gray, ACI fulfilled in some families; A diagonal line, data not available. 
Black, results indicating pathogenicity; White, results indicating non-pathogenicity; Gray, discrepancies between individual 
Nucleotide numbering reflects cDNA with +1 corresponding to the A of the ATG translation initiation codon in the reference 
Black, results indicating pathogenicity; White, results indicating non-pathogenicity; A diagonal line, data not available.
 Black, deleterious by SIFT and MAPP-MMR; White, neutral by SIFT and MAPP-MMR; Gray, deleterious by SIFT or MAPP-
Families with additional MMR gene mutations: p.A29S, MLH1:c.–27C>A; p.E460A, MSH2:deletion of exon 8, 
MSH2:p.met663fs; p.K618A, MLH1:c.1976G>A (p.R659Q), p.R659Q, MLH1:c.1852_1853AA>GC (p.K618A).
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p.M688V, p.V722I, p.A834T, p.E886G and p.V923E) have been
found in carriers of other MMR gene variations. Furthermore, seven
of these variations do not appear pathogenic, although three
(MSH2-p.N127S, MSH2-p.V722I, and MSH2-p.A834T) are indi-
cated to be deleterious by SIFTanalysis. MSH2-p.M688V is assumed
as pathogenic by both in silico results and decreased expression in
STEP3 indicating protein instability even though MSH2 protein was
detectable by IHC. Overall, the IHC data linked to these eight
variations is either incomplete or in many cases in concordance with
the additional variations found in the carriers.
The verification of the three-step model with the MSH2 variations
demonstrates that STEP2 is sufficient to assess the pathogenicity of
22/26 MSH2 VUS. The confirming role of STEP3 is important in the
four MMR proficient variations for which pathogenicity is suggested
by only one in silico result. None of the pathogenicities indicated by
only one in silico result is confirmed by STEP3.
Verification of the Three-Step Model with MSH6
Variations
Even though none of the families carrying MSH6 variations
fulfilled the AC, the variations originate from suspected LS
families with MSI-H tumor phenotypes. Only one of the 11 MSH6
variations (p.E1193K) reliably indicates pathogenicity with the
three-step approach of assessment (Table 3) as seen by the lack of
MSH6 by IHC (STEP1), by in vitro MMR deficiency (STEP2, in
silico results not available), and by reduced MSH2 interaction
Table 2. Verification Data of MSH2 Variations
a Black, ACII fulfilled; White, ACII not fulfilled; Gray, ACII fulfilled in some families; A diagonal line, data not available. 
bBlack, results indicating pathogenicity; White, results indicating non-pathogenicity; Gray, discrepancies between individual 
tumor data (MSI and IHC); A diagonal line, data not available. 
c Nucleotide numbering reflects cDNA with +1 corresponding to the A of the ATG translation initiation codon in the reference 
sequence, according to journal guidelines (www.hgvs.org/mutnomen).
d Black, results indicating pathogenicity; White, results indicating non-pathogenicity; A diagonal line, data not available.
e Black, deleterious by SIFT and MAPP-MMR; White, neutral by SIFT and MAPP-MMR; Gray, deleterious by SIFT or MAPP-
MMR only; A diagonal line, data not available
f Families with additional MMR gene mutations: p.N127S,MSH2:c.982G>C, MSH2:c.1264G>T,MLH1:c.1877del,
MLH1:c.IVS15_5T>C, MLH1:c.395T>C; p.I145M, MSH6:c.3284G>A (p.R1095H), MSH6:c.4061T>A (p.L1354Q); p.G322D,
MSH2:c.1552C>T, MLH1:c.350C>T; p.M688V, MLH1:c.350C>T, MSH6:c.4016C>T; p.V722I, MLH1:c.1039_8T>A; p.A834T,
MSH2:deletion of exon 8; p.E886G, MSH6: n/a; p.V923E, MSH6: c.3563G>A 
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f        
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f           
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f           
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f
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f        
c.2235_2240del  p.I745_I746del        
     c.2245G>A  p.E749K     
c.2500G>A  p.A834T
f        
c.2657A>G  p.E886G
f           
c.2768T>A  p.V923E
f           
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HUMAN MUTATION, Vol. 32, No. 1, 107–115, 2011 111capability (STEP3). Reduced expression of MSH6-p.G566R
(STEP3) suggests pathogenicity, which is supported by assays
measuring its ability to stimulate ATPase activity [Cyr and
Heinen, 2008; Kariola et al., 2002]. Nevertheless, MSH6-p.G566R
does not appear pathogenic in STEP2.
No indication of pathogenicity is detectable for three MSH6
variations (p.R128L, p.K728T, p.G881delinsKS) notably, all of
which lack MLH1 protein but not MSH6 (or MSH2) according to
the IHC results. The MMR deficiencies of these tumors as well as
that of MSH6-p.P623L have indeed been shown to be due to
MLH1 promoter hypermethylation [Kariola et al., 2004], suggest-
ing that these four VUS are nonpathogenic. Moreover, as seen
with 8 MSH2 VUS, an additional MMR gene variation, a
nonpathogenic MSH2-p.I145M variation has been found in both
MSH6-p.R1095H and MSH6-p.L1354Q carriers. There appears to
be no indication of MSH6-p.S144I pathogenicity; however, the in
silico results were not obtainable. MSH6-p.P1087T and MSH6-
p.P1087R on the other hand, are predicted to be deleterious by
SIFT analysis although the MMR in vitro and STEP3 analyses do
not detect defects in protein function.
Even though the 11 MSH6 variations do not compose an ideal
data set for the verification of the three-step model in assessing
VUS pathogenicity, the importance of the interpretation of tumor
IHC data prior to the identification of the VUS taken for further
assessment is highlighted. Where the loss of MLH1 is detected by
IHC, MLH1 promotor hypermethylation analysis should be
carried out prior to MSH6 mutation analysis. The applicability
of the model is further challenged by the lack of reliable in silico
predictions for MSH6 alterations and only if MSH6 deficiency is
indicated by STEP1, or by the exclusion of other causative
mutations, the verification of the three-step model is feasible.
The Necessity of STEP3 in the Three-Step Model
Only with 3/74 variations (MLH1-p.V612del, MLH1-p.K616del,
and MSH6-p.G566R) STEP3 results provided information not
already indicated by STEP2. Remarkably, all three variations lack
in silico results. Hence, STEP3 is useful for the verification of the
STEP2 assays, yet descriptive but often not necessary for the
assessment of VUS pathogenicity. The verification of the model is
indicated in terms of the amount of steps required for
pathogenicity assessment of each VUS. Figure 2 demonstrates
the collected results of each required assessment step for each gene
and its variations. STEP3 of the assessment model across the
variations of all three genes serves to confirm differences between
the results of the previous assessments. Furthermore, STEP3 can
be utilized to confirm or clarify causes of variant pathogenicity
indicated by STEP2. STEP3 of the three-step model confirms the
pathogenicity of 36 variations of which 31 is indicated by a
reduction in expression. Where STEP3 is required, expression
analysis should be the assay of choice, as only four variations
indicate pathogenicity in STEP3 by localization or interaction
analyses and not by the expression analysis.
Discussion
Based on the application of 74 MMR gene variations and
clinical data, the three-step assessment model seems to be a
Table 3. Verification Data of MSH6 Variations
a Black, ACII fulfilled; White, ACII not fulfilled; Gray, ACII fulfilled in some families; A diagonal line, data not available. 
b Black, results indicating pathogenicity; White, results indicating non-pathogenicity; Gray, discrepancies between individual 
tumor data (MSI and IHC); A diagonal line, data not available. 
c Nucleotide numbering reflects cDNA with +1 corresponding to the A of the ATG translation initiation codon in the reference 
sequence, according to journal guidelines (www.hgvs.org/mutnomen).
dBlack, results indicating pathogenicity; White, results indicating non-pathogenicity; A diagonal line, data not available. 
e Black, deleterious by SIFT and MAPP-MMR; White, neutral by SIFT and MAPP-MMR; Gray, deleterious by SIFT or MAPP-
MMR only; A diagonal line, data not available; Vertically divided field indicates the availability of one result only.
f MLH1 promoter hypermethylation found in tumors 
g  Families with additional MMR gene mutations: p.R1095H, MSH2:c.435T>G (p.I145M); p.L1354Q, MSH2:c.435T>G
(p.I145M)
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112 HUMAN MUTATION, Vol. 32, No. 1, 107–115, 2011valuable tool for correctly identifying pathogenic MMR gene
mutations, which in turn, permits predictive gene testing in the
family and enables targeted cancer surveillance. The identification
of the MMR gene for mutation analysis greatly relies on the
comprehensive use of the patient’s family history, MSI and IHC
data. The absence of an MMR protein in IHC gives a good but not
an absolute indication of the causative gene responsible for the
MSI phenotype and subsequent tumorigenesis as indicated by the
variations included in this study. Pathogenic MSH2 mutations are
shown to be highly associated with the lack of protein expression
in IHC analyses [Mangold et al., 2005; Ollila et al., 2008], which is
also frequently characterized by the absence of MSH6, the
heterodimerization partner of MSH2 [Chang et al., 2000].
Furthermore, the sensitivity of IHC in predicting pathogenic
MSH6 mutations has been said to be as high as 90% [Hendriks
et al., 2004]. However, IHC results demonstrating the lack of
MLH1 expression may be misleading as MLH1 expression is often
lost due to the hypermethylation of its promoter region [Kane
et al., 1997]. In addition, the presence of a protein cannot be
implied to indicate its functionality as pathogenicity can be caused
by functional problems not affecting the stability of the protein
[Mangold et al., 2005; Raevaara et al., 2005].
The application of the 74 variants to the three-step assessment
model suggests that pathogenicity is reliably indicated by the
STEP2 in vitro MMR assay as supported by other functional assays
in STEP3. Nonetheless, when no indication of pathogenicity is
seen in the in vitro MMR assay the importance of computational
methods become apparent. In silico methods have been shown to
have a high predictive value (88.1%) when four different methods
are in agreement [Chan et al., 2007] and alignments are manually
Figure 2. Schematic illustration of (A) MLH1 (B) MSH2, and (C) MSH6 showing the known functional domains, locations of the studied
variations, and the amount of steps required for their assessment of pathogenicity. Each required step of the three-step assessment model is
represented with a circle. STEP1 is divided to indicate the accordance of the family history with the Amsterdam criteria I/II (lower half: black, AC
fulfilled; white, AC not fulfilled; gray, AC fulfilled by some families; diagonal line, data not available) and the MSI and IHC results of the tumor
(upper half: black, MSI-H and/or reduced protein expression [IHC]; white, no MSI-H and no problems in protein expression (IHC); gray,
contradicting data between several families; diagonal line, data not available). STEP2 is divided to indicate variant protein in vitro MMR activity
(lower half: black, deficient; white, proficient) and in silico results (upper half: black, pathogenic effect predicted by SIFT and MAPP-MMR;
white, neutral effect predicted by SIFT and MAPP-MMR; gray, discordant or only one result, either pathogenic or nonpathogenic available;
diagonal line, data not available). STEP3 assay results are combined to assess VUS pathogenicity (black, results indicating pathogenicity; white,
results indicating nonpathogenicity; gray, STEP inconclusive; diagonal line, data not available).
HUMAN MUTATION, Vol. 32, No. 1, 107–115, 2011 113revised [Tavtigian et al., 2008a]. As the model proposed by Couch
et al. [2008] considers the in vitro MMR and in silico assay results
in a single step, we combined results from two in silico approaches
previously shown to be appropriate for MMR gene variations
[Chao et al., 2008; Ollila et al., 2006; Tavtigian et al., 2008b], with
those obtained from the in vitro MMR assay to verify the model
and the necessity of STEP3. A total of 28/63 MLH1 and MSH2
variations are indicated as pathogenic by both in silico methods
and in 24 of them pathogenicity is further supported by STEP3
results. Our results also suggest that in most cases where
discrepancies between SIFT and MAPP-MMR results are seen,
the in vitro MMR proficiency should be assumed correct. A single
in silico result suggesting deficiency is often linked to other
ambiguities associated to the variation and is not sufficient to
characterize the MMR variation alone as seen in the case of seven
MLH1, four MSH2, and two MSH6 variations. Of these, only three
MLH1 variations were confirmed to be pathogenic by STEP3
assays. Overall, STEP3 of the assessment model is not required in
cases where it does not provide information not already revealed
by STEP2. Variant deficiency can be indicated by the in vitro
MMR assay alone or by both in silico analyses; hence, STEP2
suffices for the characterization of most MLH1 (27/37) and MSH2
(22/26) variations. The 11 MSH6 variations applied to verify the
model present with atypical family background and should hence
be assessed with scrutiny. Regardless of the limited selection of
MSH6 variations the applicability of the three-step model to the
assessment of MSH6 variations is not ruled out—merely more
attention to STEP1 is called for in order to eliminate phenotypes
caused by other MMR genes. As our results suggest, the MSI-H
phenotype in 3/11 tumors from MSH6 VUS carriers is more likely
to be linked to the MLH1 promoter hypermethylation than MSH6
variations found in the families, and thus, if MLH1 expression is
lost in the tumor, its promoter hypermethylation should be assayed
before the more challenging and time consuming functional assays.
Only two MLH1 (p.V612del and p.K616del) and one MSH6
(p.G566R) variations of the total 74 (4%) indicate pathogenicity
in STEP3 for the first time. Of these, p.K616del pathogenicity is
supported by the AC fulfillment, MSI and IHC data, whereas
p.V612del pathogenicity is supported by only the AC fulfillment.
Here, the lack of indication of pathogenicity already in STEP2 is
probably due to the lack of in silico data, which is unfortunately
the case for in frame deletions. We also want to acknowledge that
the in vitro MMR assay was carried out using parameters, which
maintain the amount of variant protein at optimal levels for
detecting even the slightest repair. In the future, the assay could
also be titrated to allow the detection of less prominent functional
defects, possibly facilitating the assessment of carboxyl terminal
MLH1 variations, which nevertheless are currently recognized by
the combination of two in silico analyses in STEP2.
When a variation does not appear to be causative of the LS
phenotype, the presence of other predisposing variations should
be considered. Carriers of 14 VUS (four MLH1, eight MSH2, and
two MSH6) included in this verification were reported to also
carry other MMR gene variations. Unsurprisingly, only 1 (MSH2-
p.M688V) of the 14 VUS could be considered as pathogenic,
although the other mutations, MLH1 (p.T117M) and MSH6
(p.A1889V), identified in the MSH2-p.M688V carriers may also
contribute toward the LS phenotype [Christensen et al., 2008,
2009]. Another problematic VUS in terms of assessment of
pathogenicity is MLH1-p.K618A, because seven families carrying
the variation show extremely variable phenotypes in terms of MSI
and IHC. Even though its slightly decreased ability to interact with
PMS2 has been reported [Guerrette et al., 1999; Kondo et al.,
2003], p.K618A does not appear to be pathogenic by STEP2 and
STEP3 assays. Furthermore, one of the MLH1-p.K618A families
was also reported to carry MLH1-p.R659Q missense mutation
affecting a codon highly linked to the aberrant splicing and
subsequent skipping of exon 17 (p.E633_E663del) [Kohonen-
Corish et al., 1996; Nystro ¨m-Lahti et al., 1999]. Interestingly
MLH1-p.R659Q itself does not appear to be pathogenic, suchs as
other VUS (p.R659P) in the same codon. Skipping of exon 17
(MLH1-p.E633_E663del) is, however, shown to cause MMR
deficiency [Nystro ¨m-Lahti et al., 2002].
According to our verification, the three-step assessment model
is a logical and useful tool for the assessment of the pathogenicity
of MMR variations as demonstrated with the 74 VUS and their
clinical, laboratory, and computational data. When both the in
vitro MMR and the in silico assay results are available, STEP2 of
the assessment model seems to be sufficient to assess the
pathogenicity of most MLH1 and MSH2 variations. Furthermore,
STEP2 also suffices to indicate nonpathogenicity to the same
extent as STEP3, and is hence also important in guiding the
reassessment of the cause of LS susceptibility in a family. The
ultimate aim should be to obtain a classification of the VUS based
on the probability of being pathogenic, as proposed by Plon et al.
[2008] using five probability classes ranging from definitely
pathogenic to not pathogenic or of no clinical significance.
Although the results of this work are not yet sufficient to allow
application of this specific approach in the clinical setting, and at
this stage, without determined cutoffs for separate assays, the
model does not allow to consider all five classes, the results are
promising, and thus encourage the use of the model for a
comprehensive validation study against a set of VUS that have
been defined as clearly pathogenic or neutral.
References
Aaltonen LA, Peltoma ¨ki P, Leach FS, Sistonen P, Pylkka ¨nen L, Mecklin JP, Ja ¨rvinen H,
Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la
Chapelle A. 1993. Clues to the pathogenesis of familial colorectal cancer. Science
260:812–816.
Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T,
Ollila S, Nystro ¨m M, Grimm AJ, Christodoulou J, Oetting WS, Greenblatt MS.
2007. Interpreting missense variants: comparing computational methods in
human disease genes CDKN2A, MLH1, MSH2, MECP2, and Tyrosinase (TYR).
Hum Mutat 28:683–693.
Chang DK, Ricciardiello L, Goel A, Chang CL, Boland CR. 2000. Steady-state
regulation of the human DNA mismatch repair system. J Biol Chem 275:
18424–18431.
Chao EC, Velasquez JL, Witherspoon MSL, Rozek LS, Peel D, Ng P, Gruber SB,
Watson P, Rennert G, Anton-Culver H, Lynch H, Lipkin SM. 2008. Accurate
classification of MLH1/MSH2 missense variants with multivariate analysis of
protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat 29:
852–860.
Christensen LL, Kariola R, Korhonen MK, Wikman FP, Sunde L, Gerdes AM,
Okkels H, Brandt CA, Bernstein I, Hansen TVO, Hagemann-Madsen R,
Andersen CL, Nystro ¨m M, Orntoft TF. 2009. Functional characterisation of rare
missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer
patients. Familial Cancer 8:489–500.
Christensen LL, Madsen BE, Wikman FP, Wiuf C, Koed K, Tjønneland A, Olsen A,
Syva ¨nen AC, Andersen CL, Orntoft TF. 2008. The association between genetic
variants in hMLH1 and hMSH2 and the development of sporadic colorectal
cancer in the Danish population. BMC Med Genet 9:52.
Couch FJ, Rasmussen LJ, Hofstra R, Monteiro ANA, Greenblatt MS, de Wind N,
IARC unclassified variants working group. 2008. Assessment of functional
effects of unclassified genetic variants. Hum Mutat 29:1314–1326.
Cyr JL, Heinen CD. 2008. Hereditary cancer-associated missense mutations in
hMSH6 uncouple ATP hydrolysis from DNA mismatch binding. J Biol Chem
283:31641–31648.
Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. 2008.
Genetic evidence and integration of various data sources for classifying
uncertain variants into a single model. Hum Mutat 29:1265–1272.
114 HUMAN MUTATION, Vol. 32, No. 1, 107–115, 2011Guerrette S, Acharya S, Fishel R. 1999. The interaction of the human MutL
homologues in hereditary nonpolyposis colon cancer. J Biol Chem 274:
6336–6341.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakawaga H,
Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la
Chapelle A. 2005. Screening for the Lynch Syndrome (hereditary nonpolyposis
colorectal cancer). N Engl J Med 352:1851–1860.
Hendriks YMC, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F,
Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, Tops C, Van
Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB,
Breuning MH, Fodde R, Winjen JT, Bro ¨cker-Vriends AHJT, Vasen H. 2004.
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6
mutations: impact on counseling and surveillance. Gastroenterology 127:
17–25.
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM,
Kolodner R. 1997. Methylation of the hMLH1 promoter correlates with lack of
expression of hMLH1 in sporadic colon tumors and mismatch repair-defective
human tumor cell lines. Cancer Res 57:808–811.
Kariola R, Hampel H, Frankel WL, Raevaara TE, de la Chapelle A, Nystro ¨m-Lahti M.
2004. MSH6 missense mutations are often associated with no or low cancer
susceptibility. Br J Cancer 91:1287–1292.
Kariola R, Otway R, Lo ¨nnqvist KE, Raevaara TE, de la Chapelle A, Nystro ¨m-Lahti M.
2003. Two mismatch repair gene mutations found in a colon cancer patient—
which one is pathogenic? Hum Genet 112:105–109.
Kariola R, Raevaara TE, Lo ¨nnqvist KE, Nystro ¨m-Lahti M. 2002. Functional analysis
of MSH6 mutations linked to kindreds with putative hereditary non-polyposis
colorectal cancer syndrome. Hum Mol Genet 11:1303–1310.
Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, Wijnen J,
Khan PM, Macrae F, St John DL. 1996. RNA-based mutation screening in
hereditary nonpolyposis colorectal cancer. Am J Hum Genet 59:818–824.
Kondo E, Suzuki H, Horii A, Fukushige S. 2003. A yeast two-hybrid assay provides a
simple way to evaluate the vast majority of hMLH1 germ-line mutations. Cancer
Res 63:3302–3308.
Lynch HT, de la Chapelle A. 1999. Genetic susceptibility to non-polyposis colorectal
cancer. J Med Genet 36:801–818.
Mangold E, Pagenstecher C, Friedl W, Fischer HP, Merkelbach-Bruse S, Ohlendorf M,
Friedrichs N, Aretz S, Buettner R, Propping P, Mathiak M. 2005. Tumours
from MSH2 mutation carriers show loss of MSH2 expression but many
tumours from MLH1 carriers exhibit weak positive MLH1 staining. J Pathol
207:385–395.
Ng PC, Henikoff S. 2001. Predicting deleterious amino acid substitutions. Genome
Res 11:863–874.
Nystro ¨m-Lahti M, Perrera C, Ra ¨schle M, Panyushkina-Seiler E, Marra G, Curci A,
Ouaresima B, Constanzo F, D’Urso M, Venuta S, Jiricny J. 2002. Functional
analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer.
Genes Chromosomes Cancer 33:160–167.
Nystro ¨m-Lahti M, Holmberg M, Fidalgo P, Salovaara R, de la Chapelle A, Jiricny J,
Peltoma ¨ki P. 1999. Missense and nonsense mutations in codon 659 of MLH1
cause aberrant splicing of messenger RNA in HNPCC kindreds. Genes
Chromosomes Cancer 26:372–375.
Ollila S, Dermadi Bebek D, Jiricny J, Nystro ¨m M. 2008. Mechanisms of pathogenicity
in human MSH2 missense mutants. Hum Mutat 29:1355–1363.
Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F,
Kohonen-Corish M, Gerdes AM, Peltoma ¨ki P, Mangold E, de la Chapelle A,
Greenblatt M, Nystro ¨m M. 2006. Pathogenicity of MSH2 missense mutations is
typically associated with impaired repair capability of the mutated protein.
Gastroenterology 131:1408–1417.
Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS,
Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian SV, IARC Unclassified
Genetic Variants Working Group. 2008. Sequence variant classification and
reporting: recommendations for improving the interpretation of cancer
susceptibility genetic test results. Hum Mutat 29:1282–1291.
Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lo ¨nnqvist KE, Holinski-
Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltoma ¨ki P,
Kohonen-Corish M, Mangold E, Macrae F, Greenblatt M, de la Chapelle A,
Nystro ¨m M. 2005. Functional significance and clinical phenotype of nontruncat-
ing mismatch repair variants of MLH1. Gastroenterology 129:537–549.
Raevaara TE, Vaccaro C, Abdel-Rahman WM, Mocetti E, Bala S, Lo ¨nnqvist KE,
Kariola R, Lynch HT, Peltoma ¨ki P, Nystro ¨m-Lahti M. 2003. Pathogenicity of the
hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the
functional protein. Gastroenterology 125:501–509.
Stone EA, Sidow A. 2005. Physiochemical constraint violation by missense
substitutions mediates impairment of protein function and disease severity.
Genome Res 15:978–986.
Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. 2008a. Classification of rare
missense substitutions, using risk surfaces, with genetic- and molecular-
epidemiology applications. Hum Mutat 29:1342–1354.
Tavtigian SV, Greenblatt MS, Lesueur F. 2008b. In silico analysis of missense substitutions
using sequence-alignment based methods. Hum Mutat 29:1327–1336.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ru ¨schoff J, Fishel R,
Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A,
Lynch HT, Peltoma ¨ki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA,
Hawk ET, Barrett JC, Freedman AN, Srivastava S. 2004. Revised Bethesda
Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and
microsatellite instability. J Natl Cancer Inst 96:261–268.
Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. 1991. The International Collaborative
Group on Hereditary Non-polyposis Colorectal Cancer (ICG-HNPCC). Dis
Colon Rectum 34:424–425.
Vasen HFA, Watson P, Mecklin J-P, Lynch HT, the ICG-HNPCC. 1999. New clinical
criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch
syndrome) proposed by the international collaborative group on HNPCC.
Gastroenterology 116:1453–1456.
HUMAN MUTATION, Vol. 32, No. 1, 107–115, 2011 115